Targeted therapies in Pulmonary arterial Hypertension (PAH)

PDE5 inhibitors Preston[308] Non-randomised controlled study 20 patients with PAH Oral sildenafil Compared to NO, both, and IV PGI2 Potent acute fall in PVR, increase in CO. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download